Upgrade to SI Premium - Free Trial

Form SCHEDULE 13D/A PULSE BIOSCIENCES, INC. Filed by: DUGGAN ROBERT W

May 13, 2026 6:37 PM





If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D




Comment for Type of Reporting Person:
*Represents 49,706,423 shares of Common Stock, including (i) 256,078 shares of Common Stock underlying certain options exercisable within 60 days hereof, held by Mr. Duggan, (ii) 630,109 shares of Common Stock held by Genius 24C Inc d/b/a Genius Inc and (iii) 450,189 shares of Common Stock held by Blazon Corporation. This does not include options which are not exercisable in 60 days from the date hereof. The number of shares of Common Stock beneficially owned by Mr. Duggan reported in the table above does not include shares of Common Stock which are beneficially owned by Mr. Duggan's spouse, Dr. Maky Zanganeh. As spouses, Mr. Duggan and Dr. Zanganeh may be deemed to have acquired beneficial ownership of the securities held by the other spouse upon their marriage on December 18, 2024. Mr. Duggan does not hold any voting or investment power over such securities held by Dr. Zanganeh. Mr. Duggan disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. Percent beneficially owned is based on 69,141,378 shares of Common Stock outstanding, consisting of (i) 68,225,067 shares outstanding as disclosed in the Issuer's Proxy Statement filed with the Securities and Exchange Commission on May 11, 2026, (ii) 256,078 shares underlying options that can be exercised by Mr. Duggan within 60 days hereof and (iii) 660,233 shares of Common Stock issued by the Issuer through its at-the-market equity offering program.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Represents 630,109 shares of Common Stock held by Genius 24C Inc d/b/a Genius Inc. Percent beneficially owned is based on 68,885,300 shares of Common Stock outstanding, consisting of (i) 68,225,067 shares outstanding as disclosed in the Issuer's Proxy Statement filed with the Securities and Exchange Commission on May 11, 2026, and (ii) 660,233 shares of Common Stock issued by the Issuer through its at-the-market equity offering program.


SCHEDULE 13D




Comment for Type of Reporting Person:
* Represents 450,189 shares of Common Stock held by Blazon Corporation. Percent beneficially owned is based on 68,885,300 shares of Common Stock outstanding, consisting of (i) 68,225,067 shares outstanding as disclosed in the Issuer's Proxy Statement filed with the Securities and Exchange Commission on May 11, 2026, and (ii) 660,233 shares of Common Stock issued by the Issuer through its at-the-market equity offering program.


SCHEDULE 13D


ROBERT W. DUGGAN
Signature:/s/ Robert W. Duggan
Name/Title:Robert W. Duggan
Date:05/13/2026
GENIUS 24C INC
Signature:/s/ Robert W. Duggan
Name/Title:Robert W. Duggan, Authorized Signatory
Date:05/13/2026
BLAZON CORPORATION
Signature:/s/ Robert W. Duggan
Name/Title:Robert W. Duggan, Authorized Signatory
Date:05/13/2026

Categories

SEC Filings